Incyte Corp is an American pharmaceutical company based in Alapocas, Delaware. The company was founded in Palo Alto, California in 1991 and went public in 1993.
Incyte has one drug, Jakafi, which has been approved by the U.S. Food and Drug Administration and has been prescribed to patients in the United States.
As of 2014, the company was developing baricitinib, an oral JAK1 and JAK2 inhibitor drug for rheumatoid arthritis in partnership with Eli Lilly. It gained EU approval in February 2017. In April 2017, the US FDA issued a rejection, citing concerns about dosing and safety.
As of 2016 epacadostat, an indoleamine 2,3-dioxygenase inhibitor, was in development for various cancers and was in combination trials with Merck's pembrolizumab and Bristol Myers Squibb's nivolumab.
In 2013, Novartis acquired Incyte's c-Met inhibitor capmatinib.
In 2014, Incyte named Hervé Hoppenot president and CEO. Hoppenot had previously served as the president of Novartis Oncology; he had been with Novartis since 2003.
In September 2015, the company announced it had gained exclusive development and commercial right pertaining to Jiangsu Hengrui Medicine Co., Ltd's anti-PD-1 monoclonal antibody, SHR-1210, in a deal worth $795+ million.
In January 2020, Incyte signed a collaboration and license agreement for the global development and commercialization of tafasitamab with MorphoSys. On March 3, 2020, the agreement received antitrust clearance and thus became effective.
Highest paying job titles at Incyte include Director, Project Management, Research Investigator, and Medical Director